Importance of ideal cardiovascular health metrics in the risk of colorectal cancer among people aged 50 years or older: a UK Biobank cohort study

Jijuan Zhang, Hancheng Yu, Tao Huang, Ninghao Huang, Hailun Liang

ABSTRACT
Objective To explore the correlation between the ideal cardiovascular health metrics (ICVHMs) and the incidence of colorectal cancer (CRC) among people aged 50 years or older.

Design Prospective cohort study.

Setting The UK Biobank, a prospective cohort of middle-aged participants recruited between 2006 and 2010.

Participants The study included 342,226 participants from the UK Biobank aged 50 years or older without prevalent cancer.

Exposure The ICVHMs consist of four behavioural factors (abstinence from smoking, ideal body mass index (BMI), physical activity at goal and consumption of healthy diet) and three cardiometabolic factors (untreated total cholesterol <200 mg/dL, untreated blood pressure <120/80 mm Hg and untreated fasting plasma glucose <100 mg/dL).

Main outcomes The outcome was ascertained by linkage to cancer and death registries using the International Classification of Diseases, Tenth codes C18–C20.

Results During a median follow-up time of 8.72 years, 3060 CRC cases were identified. Compared with the reference (participants with ICVHMs ≤2), the multivariable-adjusted HRs for subgroups with 3, 4, 5, and ≥6 ICVHMs factors were 0.98 (95% CI 0.85 to 1.12), 0.90 (95% CI 0.77 to 1.02), 0.85 (95% CI 0.71 to 0.98) and 0.69 (95% CI 0.48 to 0.90), respectively. Among the seven ICVHM factors, lower BMI, healthier diet and ideal fasting plasma glucose were significantly associated with lower risk of CRC (HR: 0.86, 95% CI 0.78 to 0.95; HR: 0.92, 95% CI 0.84 to 0.99; HR: 0.90, 95% CI 0.80 to 0.99).

Conclusions Adherence to the ICVHMs was associated with a lower risk of CRC among people aged 50 years or older. Among the seven ICVHM factors, BMI, diet and fasting plasma glucose played a more critical role in the prevention of CRC. These findings imply that adherence to ICVHMs should be encouraged to reduce the burden of cardiovascular disease as well as CRC.

STRENGTHS AND LIMITATIONS OF THIS STUDY
⇒ This study was based on a prospective cohort with a long follow-up period and large sample size.
⇒ Outcomes were ascertained through linkage to comprehensive cancer and death registries.
⇒ We could not capture the long-term trajectories of the ideal cardiovascular health metrics due to unavailability of data sets.
⇒ Some relevant factors, such as psychosocial factors and genetic susceptibility, were not included in the model for further adjustment, which could lead to residual confounding.
⇒ Due to the low response rate in the UK Biobank, the study findings may be biased by the ‘healthy volunteer’ effect.

INTRODUCTION
Prevention of chronic diseases is essential in improving population health and reducing the global disease burden. Colorectal cancer (CRC) and cardiovascular disease (CVD) are the two significant public health concerns affecting human health worldwide. CVD remains a major cause of death and disability globally, while CRC is the second leading cause of cancer deaths and the fourth most commonly diagnosed cancer in the world.

Although they are usually regarded as two independent diseases, emerging evidence has manifested many similarities and interactions between the two. In terms of pathophysiology, they may commonly share potential pathogenic mechanisms, such as chronic inflammation, oxidative stress and altered telomere length. Some traditional cardiovascular risk factors (such as smoking, obesity, hypertension, dyslipidaemia, etc) may lead to oxidative stress and chronic inflammation of the organism, thus promoting the incidence of CVD and CRC.

In 2010, the American Heart Association (AHA) proposed the concept of ‘ideal cardiovascular health metrics (ICVHMs)’, defined as (1) the simultaneous presence of four favourable health behaviours (abstinence from smoking, ideal body mass index (BMI), physical activity at goal and consumption of...
a dietary pattern that promotes cardiovascular health); and (2) the simultaneous presence of three favourable health factors (untreated total cholesterol <200 mg/dL, untreated blood pressure <120/80 mm Hg and untreated fasting plasma glucose <100 mg/dL). Several studies have shown that ICVHMs played an essential role in preventing CVD. However, few studies have elucidated their effect on cancer, especially on CRC. Previous research showed that adherence to ICVHMs was associated with a lower incidence of cancer, except for non-melanoma skin cancer. To further explore the correlation between ICVHMs and CRC, more evidence from large population cohorts is needed. This study aimed to explore the relationship between ICVHMs and the incidence of CRC through the UK Biobank cohort.

**METHODS**

**Study population**

The UK Biobank is a prospective cohort holding unprecedented data on about 500,000 participants, recruited between 2006 and 2010. The current study initially included 384,627 participants aged 50 years or older. Before data analyses, 42,401 participants with prevalent cancer were excluded. Participants were followed until the first diagnosis date of CRC, death, loss to follow-up or 10 February 2022, whichever came first. The flow chart of the study is shown in figure 1.

**Patient and public involvement**

Patients or the public were not involved in the design, conduct, reporting or dissemination plans of our research.

![Flow chart of the study](image)
Ascertainment of CRC
The outcome was ascertained by linkage to cancer and death registries using the International Classification of Diseases, Tenth codes C18–C20. More detailed information about the outcome definition is shown in online supplemental table 1.

Assessment of ICVHMs
Based on the recommendations of the Goals and Metrics Committee of the Strategic Planning Task Force of the AHA, the ICVHMs were defined as four behavioural factors (abstinence from smoking, ideal BMI, physical activity at goal and consumption of healthy diet that promotes cardiovascular health) and three cardiometabolic factors (untreated total cholesterol <200 mg/dL, untreated blood pressure <120/80 mm Hg and untreated fasting plasma glucose <100 mg/dL). Smoking status was categorised as current or never/previous smoking, and abstinence from smoking was defined as never/previous smoking. BMI was calculated by dividing the body weight (kg) by the square of height (m²), and ideal BMI was defined as 25 kg/m². Having at least 75 min/week of vigorous activity, or 150 min/week of moderate activity, or equivalent combination was identified as physical activity at goal. The ideal diet focused on at least four of seven ideal food groups according to the dietary recommendations for cardiometabolic health. More detailed information about the definition of the ICVHMs is shown in online supplemental table 2. Each factor in the ICVHMs was classified into two categories: ‘ideal’ or ‘not ideal’. ‘Ideal’ is scored 1 point and ‘not ideal’ 0 points. Therefore, the ICVHM score ranges from 0 (the unhealthiest) to 7 (the healthiest).

Weighted standardised ICVHMs
Assuming that each factor in the ICVHMs has the same effect on the outcome may not be an optimal method. Therefore, we introduced weighted standardised ICVHMs in this study, where each factor was weighted by its association with the outcome. Weighted standardised scores were constructed using the β coefficient for each factor in the Cox proportional hazards model, taking account of other potential confounders, including age, sex, ethnic origin, education, income, Townsend index, chronic illnesses, long-standing disability or infirmity, family history of CRC, medicine use, drinking status, and mutual adjustment for other ICVHM factors. The original binary variable was multiplied by the absolute value of the β coefficient and then divided by the sum of seven absolute β values. Then, the weighted standardised ICVHMs can be obtained by adding the weighted standardised score of each factor. The weighted standardised ICVHMs ranged from 0 (the unhealthiest) to 1 (the healthiest). According to the four quantiles of the weighted standardised ICVHMs, the population was divided into five levels, with higher levels indicating healthier status.

Assessment of covariates
Covariates for this study included age (years), sex (male or female), ethnic origin (white or non-white), education (university degree or non-university degree), income (less than £18 000, £18 000–£30 999, £31 000–£51 999, £52 000–£100 000, or greater than £100 000), Townsend index (continuous), chronic illnesses (yes or no), long-standing disability or infirmity (yes or no), family history of CRC (yes or no), medicine use (yes or no), menopausal status (yes or no), hormone replacement therapy (never used or ever used), and drinking status (never drinking, previous drinking or current drinking) recorded at baseline. The Townsend index is a comprehensive indicator that measures the socioeconomic status of the community, evaluating the degree of unemployment, car-free, house-free and family overcrowding in the UK. Chronic illnesses included diabetes, CVD (heart attack, angina, stroke and high blood pressure), and severe liver and kidney diseases. Family history of CRC was defined as whether the father, mother, brothers or sisters had CRC. Medicine use referred to use of aspirin/ibuprofen or not. More detailed definitions of the covariates are shown in online supplemental table 3.

Statistical analyses
Continuous variables were expressed as mean (SD), and categorical variables were described as number (percentage). Cox proportional hazards models were used to estimate the HR and 95% CI for the association between the ICVHMs and CRC. The proportional hazards assumption was checked using Schoenfeld residuals. In the multivariable models, we adjusted for age (years), sex (male or female) and ethnic origin (white or non-white) in model 1. In model 2, we further adjusted for education (university degree or non-university degree), income (less than £18 000, £18 000–£30 999, £31 000–£51 999, £52 000–£100 000, or greater than £100 000) and Townsend index (continuous). In model 3, we further adjusted for chronic illnesses (yes or no), long-standing disability or infirmity (yes or no), family history of CRC (yes or no), medicine use (yes or no), and drinking status (never drinking, previous drinking or current drinking). When exploring the effect of each factor in the ICVHMs, the other factors were mutually adjusted. In addition, we conducted subgroup analyses by age (≥50 years and <60 years vs ≥60 years) and sex (male vs female). To test the interaction between continuous ICVHMs and grouping variables, we calculated the p values for the product terms included in the Cox proportional hazards models. We also performed the following sensitivity analyses to test the robustness of the results: (1) using threefold cross-validation to generate and validate the weighted standardised ICVHMs; (2) excluding CRC cases within the first 2 years of follow-up; and (3) excluding participants with CVD (heart attack, angina, stroke and high blood pressure). Multiple imputation was used in all analyses to minimise sample size reduction due to missing values. Imputation model included survival status, follow-up.
time, all explanatory factors and covariates. Five data sets without missing values were generated after imputation, each of which followed the same analyses. Finally, the results were pooled using Rubin’s rules. All statistical analyses were performed using R software (V.4.0.3). The rms package was used to build Cox proportional hazards models and the mice package for multiple imputation. All p values were two-sided, with statistical significance defined at p<0.05.

RESULTS
Baseline characteristics of the participants
A total of 342 226 subjects were enrolled in the study, comprising 3060 CRC cases and 339 166 non-cases. The median follow-up year was 8.72, with an IQR of 1.23. The baseline characteristics of the participants are shown in table 1.

Association between ICVHMs and incident CRC
Compared with the reference (participants with ICVHMs ≤2), the multivariable-adjusted HRs for the subgroups with 3, 4, 5 and ≥6 ICVHM factors were 0.98 (95% CI 0.85 to 1.12), 0.90 (95% CI 0.77 to 1.02), 0.85 (95% CI 0.71 to 0.98) and 0.69 (95% CI 0.48 to 0.90), respectively. When continuous ICVHMs were included in the model, the negative association between the number of ICVHMs and the risk of CRC remained significant (HR: 0.93, 95% CI 0.90 to 0.96). Among the seven ICVHM factors, ideal BMI, ideal diet and ideal fasting plasma glucose were significantly related to a lower risk of CRC (HR: 0.86, 95% CI 0.78 to 0.95; HR: 0.92, 95% CI 0.84 to 0.99; HR: 0.90, 95% CI 0.80 to 0.99). The results of model 2 and model 1 were consistent with those of model 3 (table 2).

Subgroup analyses
Consistent results were observed when analyses were stratified by age (≥250 years and <60 years vs ≥60 years) (p value for interaction=0.750) (figure 2). The inverse association between the ICVHMs and the risk of CRC might be more significant among men than women (p value for interaction=0.055) (figure 2).

Sensitivity analyses
When using weighted standardised ICVHMs, the inverse association between ICVHMs and risk of CRC remained unchanged (online supplemental table 4). Consistent results were observed when we further excluded the cases during the first 2 years of follow-up (online supplemental table 5). Finally, the results were stable after excluding participants with CVD (online supplemental table 6).

DISCUSSION
This prospective study found an inverse correlation between ICVHMs and risk of CRC over a follow-up of 8.72 years. The ICVHMs proved to successfully prevent not only CVD, but also the incidence of CRC. The inverse association between the ICVHMs and the incidence of CRC was salient in this study. Participants with ≥6 ICVHM factors had 31% lower risk of CRC than those with ≤2 ICVHM factors. Rasmussen-Torvik et al had previously examined if adherence to ICVHMs played a part in the relationship of interest. Moreover, the majority of patients with CRC were over 50 years old, and most screenings for CRC are recommended to start at the age of 50. We included participants aged 50 years or older to target high-risk groups, emphasising the importance of adhering to the ICVHMs in this population.

We found that BMI, diet and fasting plasma glucose were the three significant factors independently associated with risk of CRC. Previous epidemiological evidence showed that obesity was positively associated with incident CRC. Meta-analyses have demonstrated that a weight gain of 10 kg could result in about 8% increased risk of CRC. In contrast, weight loss through bariatric surgery reduced the risk of CRC by approximately 27%. Compared with non-obese people, obese people have disordered higher levels of insulin and leptin, but lower adiponectin levels. These disordered hormones alone or jointly promote the formation and development of CRC. In addition, adipose tissue mediates low-grade chronic inflammation by releasing various cytokines, including insulin-like growth factor (IGF), interleukin 6, tumour necrosis factor-α and plasminogen activator inhibitor-1, which promotes the proliferation, migration and metastasis signalling of tumour cells. Studies have demonstrated that processed meat might increase the risk of CRC, while dietary fibre and fatty fish were associated with a lower risk of CRC. Moreover, a meta-analysis supported the inverse association between adherence to Mediterranean diet and CRC incidence.

Through inflammation pathways or intestinal microbial environment, dietary factors notably affect the risk of CRC. Two meta-analyses reported an increased risk of CRC in patients with diabetes compared with those without diabetes (pooled relative risk: 1.26, 95% CI 1.20 to 1.31; pooled relative risk: 1.27, 95% CI 1.21 to 1.34). Higher fasting plasma glucose levels were significantly associated with an increased risk of CRC (pooled OR: 1.12, 95% CI 1.06 to 1.18), and the RR of CRC was 1.015 (95% CI 1.012 to 1.019) for each 20 mg/dL increment over the FPG. Hyperglycaemia induces elevated insulin and IGF levels, and further activates the IGF-1-PI3K-AKT-mTOR pathway, which promotes tumour growth and invasion. In addition, hyperglycaemia can increase the risk of CRC through epigenetic modifications and gene interactions.
Table 1  Baseline characteristics of the participants

| Characteristics                        | Overall                  | Number of ideal cardiovascular health metrics | ≤2 | 3   | 4   | 5   | ≥6  |
|---------------------------------------|--------------------------|-----------------------------------------------|----|-----|-----|-----|-----|
|                                       |                          |                                               |    |     |     |     |     |
|                                       | n (%)                    |                                               | 342 226 (100.0) | 37 402 (10.9) | 90 358 (26.4) | 120 151 (35.1) | 72 227 (21.1) | 22 088 (6.5) |
| Age (years)                           | 59.9 (5.5)               |                                               |                |                |                |                |                |
| Sex, n (%)                            |                          |                                               |                |                |                |                |                |
| Male                                  | 159 754 (46.7)           |                                               |                |                |                |                |                |
| Female                                | 182 472 (53.3)           |                                               |                |                |                |                |                |
| Ethnic origin, n (%)                  |                          |                                               |                |                |                |                |                |
| White                                 | 326 071 (95.3)           |                                               |                |                |                |                |                |
| Non-white                             | 16 155 (4.7)             |                                               |                |                |                |                |                |
| Education, n (%)                      |                          |                                               |                |                |                |                |                |
| University degree                     | 121 715 (35.6)           |                                               |                |                |                |                |                |
| Non-university degree                 | 220 511 (64.4)           |                                               |                |                |                |                |                |
| Income, n (%)                         |                          |                                               |                |                |                |                |                |
| Less than £18 000                     | 91 499 (26.8)            |                                               |                |                |                |                |                |
| £18 000–£30 999                       | 95 598 (27.9)            |                                               |                |                |                |                |                |
| £31 000–£51 999                       | 83 244 (24.3)            |                                               |                |                |                |                |                |
| £52 000–£100 000                      | 57 477 (16.8)            |                                               |                |                |                |                |                |
| Greater than £100 000                 | 14 408 (4.2)             |                                               |                |                |                |                |                |
| Townsend index score                  | −1.4 (3.0)               |                                               |                |                |                |                |                |
| Chronic illnesses, n (%)              |                          |                                               |                |                |                |                |                |
| Yes                                  | 123 939 (36.2)           |                                               |                |                |                |                |                |
| No                                   | 218 287 (63.8)           |                                               |                |                |                |                |                |
| Long-standing disability or infirmity, n (%) |              |                                               |                |                |                |                |                |
| Yes                                  | 117 239 (34.3)           |                                               |                |                |                |                |                |
| No                                   | 224 987 (65.7)           |                                               |                |                |                |                |                |
| Family history of colorectal cancer, n (%) |              |                                               |                |                |                |                |                |
| Yes                                  | 25 699 (7.5)             |                                               |                |                |                |                |                |
| No                                   | 316 527 (92.5)           |                                               |                |                |                |                |                |
| Medicine use, n (%)                   |                          |                                               |                |                |                |                |                |
| Yes                                  | 76 711 (22.4)            |                                               |                |                |                |                |                |
| No                                   | 265 515 (77.6)           |                                               |                |                |                |                |                |
| Menopausal status, n (%)              |                          |                                               |                |                |                |                |                |
| Yes                                  | 140 188 (76.8)           |                                               |                |                |                |                |                |
| No                                   | 12 511 (6.9)             |                                               |                |                |                |                |                |
| Not sure                              | 29 773 (16.3)            |                                               |                |                |                |                |                |
| Hormone replacement therapy, n (%)    |                          |                                               |                |                |                |                |                |
| Never used                            | 95 867 (52.5)            |                                               |                |                |                |                |                |
| Ever used                             | 86 605 (47.5)            |                                               |                |                |                |                |                |
| Drinking status, n (%)                |                          |                                               |                |                |                |                |                |
| Never drinking                        | 15 125 (4.4)             |                                               |                |                |                |                |                |
| Previous drinking                     | 12 638 (3.7)             |                                               |                |                |                |                |                |
| Current drinking                      | 314 463 (91.9)           |                                               |                |                |                |                |                |
Moreover, we found that the association between the ICVHMs and the incidence of CRC was more significant among men than women, consistent with previous studies. This may be related to the biological and behavioural differences between men and women. In

| Characteristics | Overall | ≤2 | 3 | 4 | 5 | ≥6 |
|-----------------|---------|----|---|---|---|----|
| Number of ideal cardiovascular health metrics | | | | | | |

Table 1 Continued

| Category | Cases | Person-years | Model 1 HR (95% CI) | Model 2 HR (95% CI) | Model 3 HR (95% CI) |
|----------|-------|--------------|---------------------|---------------------|---------------------|
| Smoking  |       |              |                     |                     |                     |
| Current smoking | 307 | 278 869 | 1.00 (reference)  | 1.00 (reference)  | 1.00 (reference)  |
| Never or previous smoking | 2753 | 2 666 999 | 0.92 (0.80 to 1.04) | 0.93 (0.81 to 1.05) | 0.92 (0.80 to 1.05) |
| Body mass index | | | | | | |
| >25 kg/m² | 2277 | 2 024 065 | 1.00 (reference)  | 1.00 (reference)  | 1.00 (reference)  |
| ≤25 kg/m² | 783 | 921 803 | 0.85 (0.77 to 0.94) | 0.86 (0.77 to 0.94) | 0.86 (0.78 to 0.95) |
| Physical activity | | | | | | |
| <150 min/week mixed (moderate+vigorous) activity | 592 | 534 930 | 1.00 (reference)  | 1.00 (reference)  | 1.00 (reference)  |
| ≥150 min/week mixed (moderate+vigorous) activity | 2468 | 2 410 938 | 0.91 (0.81 to 1.00) | 0.91 (0.81 to 1.00) | 0.91 (0.82 to 1.00) |
| Diet | | | | | | |
| <4 ideal food groups | 1413 | 1 256 306 | 1.00 (reference)  | 1.00 (reference)  | 1.00 (reference)  |
| ≥4 ideal food groups | 1647 | 1 689 562 | 0.92 (0.84 to 0.99) | 0.92 (0.84 to 0.99) | 0.92 (0.84 to 0.99) |
| Total cholesterol | | | | | | |
| ≥5.18 mmol/L | 1942 | 2 022 426 | 1.00 (reference)  | 1.00 (reference)  | 1.00 (reference)  |
| <5.18 mmol/L | 1118 | 923 442 | 1.06 (0.98 to 1.13) | 1.05 (0.97 to 1.13) | 1.05 (0.97 to 1.13) |
| Blood pressure | | | | | | |
| ≥120 mm Hg for SBP or ≥80 mm Hg for DBP | 2818 | 2 640 140 | 1.00 (reference)  | 1.00 (reference)  | 1.00 (reference)  |
| <120 mm Hg for SBP and <80 mm Hg for DBP | 242 | 305 728 | 0.97 (0.83 to 1.11) | 0.97 (0.83 to 1.11) | 0.98 (0.84 to 1.12) |
| Fasting plasma glucose | | | | | | |
| ≥5.56 mmol/L | 647 | 514 132 | 1.00 (reference)  | 1.00 (reference)  | 1.00 (reference)  |
| <5.56 mmol/L | 2413 | 2 431 736 | 0.89 (0.79 to 0.98) | 0.89 (0.79 to 0.99) | 0.90 (0.80 to 0.99) |
| Categorical ICVHMs, number | | | | | | |
| ≤2 | 369 | 318 977 | 1.00 (reference)  | 1.00 (reference)  | 1.00 (reference)  |
| 3 | 888 | 775 544 | 0.97 (0.84 to 1.11) | 0.98 (0.84 to 1.11) | 0.98 (0.85 to 1.12) |
| 4 | 1073 | 1 035 319 | 0.89 (0.76 to 1.01) | 0.89 (0.77 to 1.02) | 0.90 (0.77 to 1.02) |
| 5 | 598 | 624 187 | 0.84 (0.70 to 0.97) | 0.84 (0.71 to 0.98) | 0.85 (0.71 to 0.98) |
| ≥6 | 132 | 191 841 | 0.67 (0.46 to 0.88) | 0.68 (0.47 to 0.88) | 0.69 (0.48 to 0.90) |
| Continuous ICVHMs | 3060 | 2 945 868 | 0.92 (0.89 to 0.96) | 0.93 (0.89 to 0.96) | 0.93 (0.90 to 0.96) |

Model 1 was adjusted for age, sex and ethnic origin.
Model 2 was adjusted for age, sex, ethnic origin, education, income and Townsend index.
Model 3 was adjusted for age, sex, ethnic origin, education, income, Townsend index, chronic illnesses, long-standing disability or infirmity, family history of colorectal cancer, medicine use, and drinking status.
When exploring the effect of each factor in the ICVHMs, the other factors were mutually adjusted.
DBP, diastolic blood pressure; ICVHM, ideal cardiovascular health metrics; SBP, systolic blood pressure.
this study, the ICVHM factors among men tended to be non-ideal compared with women.

Our research has several advantages. One strength is that it was based on a prospective cohort with a long follow-up period and a large sample size, enhancing the study’s representativeness and methodological robustness. In addition, the outcome was ascertained through linkage to cancer and death registries, which are comprehensive and reliable.

However, limitations should be considered. First, this study only explored the relationship between the baseline exposures and the outcome. It did not consider changes in exposure measurements during the follow-up due to unavailability of data sets. Second, some relevant factors, such as psychosocial factors and genetic susceptibility, were not included in the model for further adjustment, which could lead to residual confounding. Third, the AHA recommended defining dietary goals according to ‘the Dietary Approaches to Stop Hypertension (DASH)’ eating plan, including sodium, sugar-sweetened beverages and so on. However, we did not evaluate adherence to DASH diet since a valid diet recording was difficult in large epidemiological studies. Fourth, due to the low response rate in the UK Biobank, the study findings may be biased by the ‘healthy volunteer’ effect. However, a previous study has shown that risk factor associations in the UK Biobank seemed to be generalisable despite a very low response rate. Finally, the study participants were mostly white. Therefore, generalisation of the findings to other populations should be cautiously applied due to differences in genetic background and other risk factors among different ethnic groups.

CONCLUSIONS
In this study, we verified that adherence to ICVHMs could reduce the risk of CRC among people aged 50 years or older. Among the seven ICVHM factors, BMI, diet and...
fasting plasma glucose played a more critical role in the prevention of CRC. Moreover, the inverse association between the ICVHMs and the risk of CRC might be more significant among men than women. These findings imply that health recommendations related to ICVHMs can be encouraged to reduce the burden of CVD as well as CRC.

Contributors JZ and HY contributed equally to this work. JZ, HY, HL and TH had full access to all of the data in the study and took responsibility for the data integrity and accuracy of the data analyses. JZ drafted the initial manuscript. NH was responsible for data extraction. HL and TH revised the manuscript. HL was responsible for the overall content as the guarantor. All authors read and approved the final manuscript.

Funding This work was supported by the National Natural Science Foundation of China (grant number: 71804183).

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not required.

Ethics approval The UK Biobank study was approved by the National Information Governance Board for Health and Social Care in England and Wales, and the Community Health Index Advisory Group in Scotland and the North West Multi-centre Research Ethics Committee.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. The UK Biobank is an open access resource. Data are available on application to the UK Biobank (www.ukbiobank.ac.uk). This research has been conducted using the UK Biobank resource under application number 44430. Data and statistical codes used for this paper are available to other researchers on request by email to Hailun Liang (hliang@ruc.edu.cn).

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is

ORCID iDs Jijuian Zhang http://orcid.org/0000-0002-2860-9673
Tao Huang http://orcid.org/0000-0002-0328-1368

REFERENCES
1 Geneau R, Stuckler D, Stachenko S, et al. Raising the priority of preventing chronic diseases: a political process. Lancet 2010;376:1689–98.
2 Writing Committee, Smith SC, Collins A, et al. Our time: a call to save preventable death from cardiovascular disease (heart disease and stroke). Glob Heart 2012;7:297–305.
3 GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the global burden of disease study 2017. Lancet 2018:392:1736–88.
4 Estruch R, Ruilope LM, Cosentino F. The year in cardiovascular medicine 2020: epidemiology and prevention. Eur Heart J 2021;42:913–21.
5 Ten Cate H. Colorectal cancer and cardiovascular disease: a thrombo-inflammatory link? Eur J Intern Med 2021;87:15–17.
6 Johnson CB, Davis MK, Law A, et al. Shared risk factors for cardiovascular disease and cancer: implications for preventive health and clinical care in oncology patients. Can J Cardiol 2016;32:900–7.
7 Zhang C, Cheng Y, Luo D, et al. Association between cardiovascular risk factors and colorectal cancer: a systematic review and meta-analysis of prospective cohort studies. EClinicalMedicine 2021;34:100794.
8 Steven S, Frenis K, Oelze M, et al. Vascular inflammation and oxidative stress: major triggers for cardiovascular disease. Oxid Med Cell Longev 2019;2019:1–26.
9 Lloyd-Jones DM, Hong Y, Labarde D, et al. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American heart association’s strategic impact goal through 2020 and beyond. Circulation 2010;121:586–613.
10 Ying Y, Lin S, Kong F, et al. Ideal cardiovascular health metrics and incidence of ischemic stroke among hypertensive patients: a prospective cohort study. Front Cardiovasc Med 2020;7:590809.
11 Wang T, Lu J, Su Q, et al. Ideal cardiovascular health metrics and major cardiovascular events in patients with prediabetes and diabetes. JAMA Cardiol 2019;4:874–83.
12 Wang D, Zhang Q, Wang A, et al. Ideal cardiovascular health metrics on the new occurrence of peripheral artery disease: a prospective cohort study in northern China. Sci Rep 2020;10:9660.
13 Rasmussen-Torvik LJ, Shay CM, Abramson JG, et al. Ideal cardiovascular health is inversely associated with incident cancer: the Atherosclerosis risk in Communities study. Circulation 2013;127:1270–5.
14 Mozaffarian D. Dietary and policy priorities for cardiovascular disease, diabetes, and obesity: a comprehensive review. Circulation 2016;133:187–225.
15 Giltonse MS. The importance of normalisation in the construction of deprivation indices. J Epidemiol Community Health 1995;49:Suppl 2:545–50.
16 Hess KR. Graphical methods for assessing violations of the proportional hazards assumption in COX regression. Stat Med 1995;14:1707–23.
17 Schoenfield D. Partial residuals for the proportional hazards regression model. Biometrika 1982;69:239–41.
18 Refaellizadeh P, Tang L, Liu H. Cross-validation. In: Liu L, Ölsz MT, eds. Encyclopedia of database systems. Boston: Springer, 2009: 532–8.
19 Buuren S, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained Equations in R. J Stat Softw 2011;45:1–67.
20 Folsom AR, Yatsuma H, Nettleton JA, et al. Community prevalence of ideal cardiovascular health, by the American heart association definition, and relationship with cardiovascular disease incidence. J Am Coll Cardiol 2011;57:1690–6.
21 Fan C, Zhang Q, Zhang S, et al. Association of newly found asymptomatic intracranial artery stenosis and ideal cardiovascular health metrics in Chinese community population. Sci Rep 2020;10:7200.
22 Kuipers EJ, Grady WM, Lieberman D, et al. Colorectal cancer. Nat Rev Dis Primers 2015;1:15065.
23 Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet 2014;383:1490–502.
24 Garcia H, Song M. Early-life obesity and adulthood colorectal cancer risk: a meta-analysis. Rev Panam Salud Publica 2019;43:1–8.
25 Dong Y, Zhou J, Zhu Y, et al. Abdominal obesity and colorectal cancer risk: systematic review and meta-analysis of prospective studies. Biosci Rep 2017;37:BSR20170945.
26 Nam GE, Baek S-J, Choi HB, et al. Association between abdominal obesity and incident colorectal cancer: a nationwide cohort study in Korea. Cancers 2020;12:1368.
27 Choi YJ, Lee DH, Han K-D, et al. Abdominal obesity, glucose intolerance and decreased high-density lipoprotein cholesterol as components of the metabolic syndrome are associated with the development of colorectal cancer. Eur J Epidemiol 2018;33:1077–85.
28 Bull CJ, Bell JA, Murphy N, et al. Adiposity, metabolites, and colorectal cancer risk: Mendelian randomization study. BMC Med 2020;18:396.
29 Schlesinger S, Aleksandrova K, Abar L, et al. Adult weight gain and colorectal adenomas—a systematic review and meta-analysis. Eur J Epidemiol 2012;27:381–92.
30 Chen Q, Wang J, Yang J, et al. Adult weight gain and colorectal adenomas—a systematic review and meta-analysis. Eur J Epidemiol 2012;27:381–92.
31 Chang S-H, Stoll CRT, Song J, et al. The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003–2012. JAMA Surg 2014;149:275–87.
| 32 | Afshar S, Kelly SB, Seymour K, et al. The effects of bariatric surgery on colorectal cancer risk: systematic review and meta-analysis. *Obes Surg* 2014;24:1793–9. |
| 33 | Renen A G, Frystyk J, Flyvbjerg A. Obesity and cancer risk: the role of the insulin-IGF axis. *Trends Endocrinol Metab* 2006;17:328–36. |
| 34 | Engin A. Diet-induced obesity and the mechanism of leptin resistance. *Adv Exp Med Biol* 2017;960:381–97. |
| 35 | De Rosa A, Monaco ML, Capasso M, et al. Adiponectin oligomers as potential indicators of adipose tissue improvement in obese subjects. *Eur J Endocrinol* 2013;169:37–43. |
| 36 | Ye P, Xi Y, Huang Z, et al. Linking obesity with colorectal cancer: epidemiology and mechanistic insights. *Cancers* 2020;12:1408. |
| 37 | Ellulu MS, Patimah I, Khazaai H, et al. Obesity and inflammation: the linking mechanism and the complications. *Arch Med Sci* 2017;13:851–63. |
| 38 | Fletcher R, Wang Y-J, Schoen RE, et al. Colorectal cancer prevention: immune modulation taking the stage. *Biorchim Biophys Acta Rev Cancer* 2018;1869:138–48. |
| 39 | Li X, Larsson P, Ljuslinder I, et al. Ex vivo organoid cultures reveal the importance of the tumor microenvironment for maintenance of colorectal cancer stem cells. *Cancers* 2020;12:923. |
| 40 | Bradbury KE, Murphy N, Key TJ. Diet and colorectal cancer in UK Biobank: a prospective study. *Int J Epidemiol* 2020;49:246–58. |
| 41 | Veettil SK, Wong TY, Loo YS, et al. Role of diet in colorectal cancer incidence: umbrella review of meta-analyses of prospective observational studies. *JAMA Netw Open* 2021;4:e2037341. |
| 42 | Alegria-Lerubundi I, Aguiro C, Bujanda L, et al. Food groups, diet quality and colorectal cancer risk in the Basque country. *World J Gastroenterol* 2020;26:4108–25. |
| 43 | Zhong Y, Zhu Y, Li Q, et al. Association between Mediterranean diet adherence and colorectal cancer: a dose-response meta-analysis. *Am J Clin Nutr* 2020;111:1214–25. |
| 44 | Shivappa N, Gods J, Hébert J, et al. Dietary inflammatory index and colorectal cancer risk—a meta-analysis. *Nutrients* 2017;9:1043. |
| 45 | Ocvirk S, Wilson AS, Appolonia CN, et al. Fiber, fat, and colorectal cancer: new insight into modifiable dietary risk factors. *Curr Gastroenterol Rep* 2019;21:62. |
| 46 | Soiri F, Dinu M, Pagliai G, et al. Fecal microbiome as determinant of the effect of diet on colorectal cancer risk: comparison of meat-based versus pesco-vegetarian diets (the MeaTIC study). *Trials* 2019;20:688. |
| 47 | Deng L, Gui Z, Zhao L, et al. Diabetes mellitus and the incidence of colorectal cancer: an updated systematic review and meta-analysis. *Dig Dis Sci* 2012;57:1576–85. |
| 48 | Tsilidis KK, Kasimis JC, Lopez DS, et al. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. *BMJ* 2015;350:g7607. |
| 49 | Xu J, Ye Y, Wu H, et al. Association between markers of glucose metabolism and risk of colorectal cancer. *BMJ Open* 2016;6:e011430. |
| 50 | Shi J, Xiong L, Li J, et al. A linear dose-response relationship between fasting plasma glucose and colorectal cancer risk: systematic review and meta-analysis. *Sci Rep* 2015;5:17591. |
| 51 | Lega IC, Lipscombe LL. Review: diabetes, obesity, and cancer-pathophysiology and clinical implications. *Endocr Rev* 2020;41:33–52. |
| 52 | Cheng H-C, Chang T-K, Su W-C, et al. Narrative review of the influence of diabetes mellitus and hyperglycemia on colorectal cancer risk and oncological outcomes. *Transl Oncol* 2021;14:101089. |
| 53 | Kirkegaard H, Johnsen NF, Christensen J, et al. Association of adherence to lifestyle recommendations and risk of colorectal cancer: a prospective Danish cohort study. *BMJ* 2010;341:c5504. |
| 54 | Aleksandrova K, Pischon T, Jenab M, et al. Combined impact of healthy lifestyle factors on colorectal cancer: a large European cohort study. *BMC Med* 2014;12:168. |
| 55 | Cook MB, Dawsey SM, Freedman ND, et al. Sex disparities in cancer incidence by period and age. *Cancer Epidemiol Biomarkers Prev* 2011;20:1629–37. |
| 56 | Edgren G, Liang L, Adami H-O, et al. Enigmatic sex disparities in cancer incidence. *Eur J Epidemiol* 2012;27:187–96. |
| 57 | Cook MB, McGlynn KA, Devesa SS, et al. Sex disparities in cancer mortality and survival. *Cancer Epidemiol Biomarkers Prev* 2011;20:1629–37. |
| 58 | Betty GD, Gale CR, Kivimäki M, et al. Comparison of risk factor associations in UK Biobank against representative, general population based studies with conventional response rates: prospective cohort study and individual participant meta-analysis. *BMJ* 2020;368:m131. |